ArticleMolecular neurobiology2025
The Role of HbA1c in Parkinson's Disease: An Integrative Analysis by Single-Cell, Bulk Transcriptome and Mendelian Randomization.
Article in Molecular neurobiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Decreased glucose tolerance is recognized as a factor associated with Parkinson's disease (PD) progression, yet the relationship between HbA1c and PD prognosis remains insufficiently explored. Using data from the Integrated Epidemiological Unit (IEU) open Genome-Wide Association Study (GWAS), PD's IEU-b-7 and HbA1c's IEU-b-104 were extracted. RNA-seq data from GSE20292 and single-cell RNA-seq data from GSE157783 were retrieved from Gene Expression Omnibus (GEO). Mendelian Randomization (MR) analysis, with HbA1c as the exposure and PD as the outcome, was performed using the inverse variance weighted (IVW) method. Differentially expressed genes (DEGs) between PD and controls in GSE20292 were identified, and overlapping instrumental variables (IVs) and DEGs pinpointed a set of candidate genes. Machine learning refinement selected biomarkers, leading to the development of a PD biomarker-based nomogram. Key cell lineages in GSE140231 were characterized, and communication and pseudotime analyses explored cell crosstalk and evolution. Using 223 independent single nucleotide polymorphisms (SNPs)as IVs, HbA1c was found causally [IVW: Odds Ratio (OR) = 1.438, P = 0.026, 95% Confidence Interval (CI) = 1.043-1.981].. Among 625 genes associated with these SNPs, 842 DEGs were identified by comparing PD vs. controls, intersecting with 27 candidate genes. Notably, five biomarkers-FASN, MICAL3, TCIRG1, CDK10, and MFSD1-emerged as potential diagnostic targets for PD. The receiver operating characteristic (ROC) curve demonstrated the high diagnostic accuracy of these biomarkers. Analysis of key cell lineages revealed strong interactions between excitatory and inhibitory cells and oligodendrocyte precursor cells and Astrocytes cells. In conclusion, HbA1c is identified as a risk factor for PD, with FASN, MICAL3, TCIRG1, CDK10, and MFSD1 representing promising targets for PD diagnosis and treatment.
Indexed as
Identifiers
40397357What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.